Ozempic & Surgery: Aspiration Risk Delays Procedures

A growing, and potentially life-threatening, complication is emerging in operating rooms: patients on Ozempic and similar drugs are experiencing delayed gastric emptying, increasing the risk of serious complications during surgery. This isn’t simply a matter of individual oversight; it reflects a broader challenge as the rapid adoption of GLP-1 agonists – hailed as breakthrough medications for weight loss and diabetes – outpaces the medical community’s established protocols for anesthetic care.

The core issue is pulmonary aspiration – when stomach contents enter the lungs. While relatively rare, the consequences can be devastating, ranging from lung injury and infection to, in severe cases, death. GLP-1 agonists, like Ozempic, Wegovy, and Mounjaro, work by mimicking a natural hormone that regulates appetite and slows gastric emptying. This is beneficial for weight management and blood sugar control, but it presents a significant challenge under anesthesia, where reflexes that normally protect the airway are suppressed. The stomach doesn’t clear as quickly, increasing the volume of potentially regurgitated material.

This situation highlights a critical lag in medical adaptation. The widespread use of these drugs is relatively recent, surging in popularity over the past 18-24 months, fueled by both prescription and off-label use. The initial excitement surrounding their efficacy in weight loss, recently endorsed by the World Health Organization, overshadowed the need for immediate adjustments to standard anesthetic procedures. The fact that approximately 500,000 Australians are now on GLP-1 medications underscores the scale of this emerging issue.

The Forward Look: What Happens Next?

The immediate response – updated guidelines from ANZCA – is a necessary first step. However, this is likely just the beginning. Expect several key developments in the coming months:

• Refined Anesthetic Protocols: Anaesthetists will likely adopt more cautious approaches, potentially including longer fasting periods (beyond the standard six hours) or the use of specialized techniques to protect the airway during intubation, as Dr. Viliunas described.
• Increased Patient Education: A concerted effort to educate patients about the importance of disclosing GLP-1 use to their healthcare providers is crucial. This will require clear communication from doctors, pharmacists, and public health campaigns.
• Further Research: More robust research is needed to quantify the increased risk of aspiration in patients on GLP-1s and to determine the optimal timing for discontinuing the medication before surgery (currently, the duration of the drug’s effect on gastric emptying remains somewhat unclear).
• Potential for Pre-Operative Monitoring: We may see the introduction of pre-operative gastric emptying studies for patients on these medications to assess individual risk levels.

The situation also raises a broader question about the speed at which medical practice adapts to rapidly evolving pharmaceutical landscapes. As new, highly effective drugs enter the market, proactive assessment of potential anesthetic implications will be essential to ensure patient safety. The current Ozempic challenge serves as a potent reminder that medical innovation must be accompanied by equally rapid adaptation in clinical practice and a commitment to open communication between patients and their healthcare teams.

Ultimately, the message from medical professionals is clear: honesty about medication use is paramount. As Professor Story emphasized, doctors are not there to judge, but to provide the safest possible care, and that requires complete and accurate information.